(Q44119946)

30 November 2017

0 references

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms (English)

1 reference

30 November 2017

1 reference

Jonathan R T Davidson

1

1 reference

30 November 2017

Paolo Meoni

2

1 reference

30 November 2017

Vincent Haudiquet

3

1 reference

30 November 2017

Marc Cantillon

4

1 reference

30 November 2017

David Hackett

5

1 reference

30 November 2017

publication date

1 January 2002

1 reference

30 November 2017

published in

Depression and Anxiety

1 reference

30 November 2017

volume

16

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

4-13

1 reference

Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects

30 November 2017

cites work

1 reference

Follow-up and family study of anxious depression

21 January 2018

1 reference

Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data

21 January 2018

1 reference

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

21 January 2018

1 reference

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

21 January 2018

1 reference

Exactly what does the Hamilton Depression Rating Scale measure?

21 January 2018

1 reference

The side effects burden of extended imipramine treatment of panic disorder.

21 January 2018

1 reference

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

21 January 2018

1 reference

Recognition, management, and course of anxiety and depression in general practice.

21 January 2018

1 reference

Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking

21 January 2018

1 reference

Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects.

21 January 2018

1 reference

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

Anxious depressions. Clinical, family history, and naturalistic outcome--comparisons with panic and major depressive disorders.

21 January 2018

1 reference

Outcome of panic and depression in a seven-year follow-up: results of the Zurich study.

21 January 2018

1 reference

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

21 January 2018

1 reference

The Hamilton depression scale. Evaluation of objectivity using logistic models

21 January 2018

1 reference

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

7 January 2021

Response characteristics to antidepressants and placebo in post-traumatic stress disorder

1 reference

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

7 January 2021

Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications.

1 reference

7 January 2021

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

7 January 2021

Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy

1 reference

7 January 2021

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

7 January 2021

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.10045

1 reference

30 November 2017

1 reference